Fuzuloparib

Fuzuloparib

Clinical data
Trade names	AiRuiYi
Other names	Fluzoparib; SHR3162
Identifiers
IUPAC name 4-[[4-Fluoro-3-[2-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrazine-7-carbonyl]phenyl]methyl]-2H-phthalazin-1-one
CAS Number	1358715-18-0
PubChem CID	56649297
DrugBank	DB15637
UNII	TWF0ML1CK8
ChEMBL	ChEMBL3930624
Chemical and physical data
Formula	C22H16F4N6O2
Molar mass	472.404 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN2C(=NC(=N2)C(F)(F)F)CN1C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
InChI InChI=InChI=1S/C22H16F4N6O2/c23-16-6-5-12(10-17-13-3-1-2-4-14(13)19(33)29-28-17)9-15(16)20(34)31-7-8-32-18(11-31)27-21(30-32)22(24,25)26/h1-6,9H,7-8,10-11H2,(H,29,33) Key:XJGXCBHXFWBOTN-UHFFFAOYSA-N

Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. ^[1] It is approved for use in China. ^[2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme. ^[3]

It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer. ^[2]

References

1. Li N, Liu Q, Tian Y, Wu L (November 2022). "Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective". Journal of Gynecologic Oncology. 33 (6) e86. doi:10.3802/jgo.2022.33.e86. PMC   9634097 . PMID   36335989.
2. Lee A (July 2021). "Fuzuloparib: First Approval". Drugs. 81 (10): 1221–1226. doi:10.1007/s40265-021-01541-x. PMC   8380563 . PMID   34118019.
3. "Fuzuloparib - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG.